Recce Pharmaceuticals Limited (ASX:RCE) Executive Director, James Graham presents on the company's lead prodct RECCE 327 for use in targeting antibiotic-resistant bacteria, its US FDA approval pathway and a Phase 1 clinical trial.
- A whole new class of antibiotic
- RECCE 327 - a broad spectrum antibiotic for sepsis
- Qualified Infectious Disease Product - 10 Years market exclusivity (post approval)
- Patented manufacturing to Phase I and II volumes
- In discussion with US Food and Drug Administration
- Publicly listed on the ASX 2016
For more, watch the Executive Director, James Graham present.